Biogen brags of Phase III data for would-be Aubagio rival oral MS drug

Share this article:
A study published in the New England Journal of Medicine indicates that Biogen Idec's experimental MS drug, BG-12 is on track to make an impression. The study said patients taking the oral medication had a significantly lower annual relapse rate at two years when taking the drug two or three times a day, compared with placebo. The study did not show the drug had any significant impact on slowing disease progression.

Thursday's news brings the drug one step closer to its built-in fan base. It also comes a week after the FDA approved Sanofi's oral contender, Aubagio (teriflunomide). Phase III trials of Sanofi's therapy reduced the relapse rate among MS patients by about 30%. Industry watchers told MM&M at the time that the approval expanded patient options, but it was going to have a longer acceptance curve among physicians than BG-12, which has cultivated a level of pre-approval confidence with its safety and efficacy profile.

Ben Weintraub, director of research at the health analytics firm InThought, told MM&M at the time of Sanofi's Augbagio approval that this will translate into doctor preference for the Biogen Idec drug over rivals like Aubagio or Tysabri for second-line use when interferon and Copaxone fail.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.